Adverse Event (AE) monitoring of ABT-199 in combination with decitabine and azacitidine Measured from Day 1 up to 2 years after the last subject has enrolled [clinicaltrials_resource:0b3df43592d9c7d37fb74a9fef5cc90f]
AE monitoring will be assessed by evaluation of study drug exposure, AEs , serious AEs, all deaths, as well as laboratory determinations and vital sign parameters.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Adverse Event (AE) monitoring of ABT-199 in combination with decitabine and azacitidine Measured from Day 1 up to 2 years after the last subject has enrolled [clinicaltrials_resource:0b3df43592d9c7d37fb74a9fef5cc90f]
AE monitoring will be assessed by evaluation of study drug exposure, AEs , serious AEs, all deaths, as well as laboratory determinations and vital sign parameters.
Bio2RDF identifier
0b3df43592d9c7d37fb74a9fef5cc90f
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:0b3df43592d9c7d37fb74a9fef5cc90f
measure [clinicaltrials_vocabulary:measure]
Adverse Event (AE) monitoring of ABT-199 in combination with decitabine and azacitidine
time frame [clinicaltrials_vocabulary:time-frame]
Measured from Day 1 up to 2 years after the last subject has enrolled
description
AE monitoring will be assessed ...... ons and vital sign parameters.
identifier
clinicaltrials_resource:0b3df43592d9c7d37fb74a9fef5cc90f
title
Adverse Event (AE) monitoring ...... the last subject has enrolled
@en
type
label
Adverse Event (AE) monitoring ...... df43592d9c7d37fb74a9fef5cc90f]
@en